Hyperoxaluria – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 4 PAGES: 34

More Info
									                      Hyperoxaluria – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1824IDB
                                                                                             Publication Date: March 2012




Hyperoxaluria – Pipeline Review, H1 2012                                                    GMDHC1824IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(1)
Hyperoxaluria – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 3
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Hyperoxaluria Overview ..................................................................................................................................................................... 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Hyperoxaluria ..................................................................................................................... 7
Hyperoxaluria Therapeutics under Development by Companies........................................................................................................ 9
Hyperoxaluria Therapeutics under Investigation by Universities/Institutes ....................................................................................... 10
Late Stage Products ......................................................................................................................................................................... 11
    Comparative Analysis .................................................................................................................................................................. 11
Mid Clinical Stage Products.............................................................................................................................................................. 12
    Comparative Analysis .................................................................................................................................................................. 12
Pre-Clinical Stage Products.............................................................................................................................................................. 13
    Comparative Analysis .................................................................................................................................................................. 13
Hyperoxaluria Therapeutics – Products under Development by Companies.................................................................................... 14
Hyperoxaluria Therapeutics – Products under Investigation by Universities/Institutes ..................................................................... 15
Companies Involved in Hyperoxaluria Therapeutics Development .................................................................................................. 16
    OxThera AB ................................................................................................................................................................................. 16
    ReGenX Biosciences, LLC .......................................................................................................................................................... 17
    Amsterdam Molecular Therapeutics BV ...................................................................................................................................... 18
Hyperoxaluria – Therapeutics Assessment ...................................................................................................................................... 19
    Assessment by Monotherapy Products ....................................................................................................................................... 19
    Assessment by Route of Administration ...................................................................................................................................... 20
    Assessment by Molecule Type .................................................................................................................................................... 22
Drug Profiles..................................................................................................................................................................................... 24
    AMT-030 - Drug Profile ................................................................................................................................................................ 24
         Product Description................................................................................................................................................................. 24
         Mechanism of Action ............................................................................................................................................................... 24
         R&D Progress ......................................................................................................................................................................... 24
    Cystadane - Drug Profile ............................................................................................................................................................. 25
         Product Description................................................................................................................................................................. 25
         Mechanism of Action ............................................................................................................................................................... 25
         R&D Progress ......................................................................................................................................................................... 25
    Oxabact - Drug Profile ................................................................................................................................................................. 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    AAV8 - Drug Profile ..................................................................................................................................................................... 28
         Product Description..........................................................................................................................................................
								
To top